Hematological ratios as prognostic indicators in patients with triple-negative breast cancer in southern Brazil
DOI:
https://doi.org/10.29289/2594539420210059Keywords:
breast cancer, triple negative breast neoplasms, prognosis, blood cell countAbstract
ABSTRACT: Introduction: The heterogeneous nature and intrinsically aggressive tumor pathology of the triple negative breast cancer subtype results in an unfavorable prognosis and limited clinical success. The use of hematological components of the systemic inflammatory response for patients with triple-negative breast cancer can add important prognostic information to the criteria traditionally used for cancer patients, since inflammation can promote tumor progression support by affecting the stages of tumorigenesis. Objectives: The aim of this study was to evaluate the hematological parameters neutrophil/lymphocyte, monocyte/lymphocyte and platelet/lymphocyte ratios as prognostic indicators in patients with triple-negative breast cancer. Methods: This was a single-center retrospective observational study in an oncology referral hospital in the South region of Brazil. Electronic medical records of patients diagnosed with triple-negative breast cancer from 2012 to 2016 were reviewed and analyzed using SPSS. Results: The low blood cell ratio groups had significantly higher overall survival than the high blood cell ratio groups. Univariate analysis also confirmed the correlation of patients in the high blood cell ratio groups with unfavorable results. Conclusions: Hematological components of the systemic inflammatory response are promising prognostic indicators. More studies on the subject should be carried out to assist in future medical decision-making so these parameters of easy assessment and low cost can be introduced in clinical practice.
Downloads
References
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49. https://doi.org/10.3322/caac.21660
2. Wahba HA, El-Hadaad HA. Current approaches in treatment of triple-negative breast cancer. Cancer Biol Med. 2015;12(2):106-16. https://doi.org/10.7497/j.issn.2095-3941.2015.0030
3. Stival RA, Martins LRA, Paganini J, Caixeta GN, Manoel WJ, Paula EC, et al. Impacto do fenótipo triplo-negativo no prognóstico de pacientes com câncer de mama de uma unidade de referência no Brasil central. Rev Bras Mastologia. 2012;22(1):6-12.
4. Silva JL, Nunes NCC, Izetti P, Mesquita GG, Melo AC. Triple negative breast cancer: a thorough review of biomarkers. Crit Rev Oncol Hematol. 2020;145:102855. https://doi.org/10.1016/j.critrevonc.2019.102855
5. Pistelli M, Lisa M, Ballatore Z, Caramanti M, Pagliacci A, Battelli N, et al. Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients. BMC Cancer. 2015;15:195. https://doi.org/10.1186/s12885-015-1204-2
6. Jia W, Wu J, Jia H, Yang Y, Zhang X, Chen K, et al. The peripheral blood neutrophil-to-lymphocyte ratio is superior to the lymphocyte-to-monocyte ratio for predicting the long-term survival of triple-negative breast cancer patients. PLoS One. 2015;10(11):e0143061. https://doi.org/10.1371/journal.pone.0143061
7. Huszno J, Kolosza Z. Prognostic value of the neutrophil‑lymphocyte, platelet‑lymphocyte and monocyte‑lymphocyte ratio in breast cancer patients. Oncol Lett. 2019;18(6):6275-83. https://doi.org/10.3892/ol.2019.10966
8. Rubio ÂDS. Razão entre células sanguíneas como indicadores de prognóstico em pacientes com câncer de mama luminal [dissertação]. Porto Alegre: Universidade Federal de Ciências da Saúde de Porto Alegre, 2020.
9. Krenn-Pilko S, Langsenlehner U, Thurner EM, Stojakovic T, Pichler M, Gerger A, et al. The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients. Br J Cancer. 2014;110(10):2524-30. https://doi.org/10.1038/bjc.2014.163
10. Romero-Cordoba S, Meneghini E, Sant M, Iorio MV, Sfondrini L, Paolini B, et al. Decoding immune heterogeneity of triple negative breast cancer and its association with systemic inflammation. Cancers (Basel). 2019;11(7):911. https://doi.org/10.3390/cancers11070911
11. Asano Y, Kashiwagi S, Onoda N, Noda S, Kawajirir H, Takashima T, et al. Platelet-lymphocyte ratio as a useful predictor of the therapeutic effect of neoadjuvant chemotherapy in breast cancer. PLoS One. 2016;11(7):e0153459. https://doi.org/10.1371/journal.pone.0153459
12. Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124. https://doi.org/10.1093/jnci/dju124
13. Wariss BR, Abrahão KS, Aguiar SS, Bergmann A, Thuler LCS. Effectiveness of four inflammatory markers in predicting prognosis in 2374 women with breast cancer. Maturitas. 2017;101:51-6. https://doi.org/10.1016/j.maturitas.2017.04.015
14. Guo W, Lu X, Liu Q, Zhang T, Li P, Qiao W, et al. Prognostic value of neutrophil‐to‐lymphocyte ratio and platelet‐to‐lymphocyte ratio for breast cancer patients: an updated meta‐analysis of 17079 individuals. Cancer Med. 2019;8(9):4135-48. https://doi.org/10.1002/cam4.2281
15. Tan D, Fu Y, Su Q, Wang H. Prognostic role of platelet-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Medicine (Baltimore). 2016;95(24):e3837. https://doi.org/10.1097/MD.0000000000003837
16. Lee S, Oh SY, Kim SH, Lee JH, Kim MC, Kim KH, et al. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy. BMC Cancer. 2013;13:350. https://doi.org/10.1186/1471-2407-13-350
17. Asher V, Lee J, Innamaa A, Bali A. Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer. Clin Transl Oncol. 2011;13(7):499-503. https://doi.org/10.1007/s12094-011-0687-9
18. Zhao QT, Yuan Z, Zhang H, Zhang XP, Wang HE, Wang ZK, et al. Prognostic role of platelet to lymphocyte ratio in non‐small cell lung cancers: a meta‐analysis including 3,720 patients. Int J Cancer. 2016;139(1):164-70. https://doi.org/10.1002/ijc.30060
19. Zhang M, Huang XZ, Song YX, Gao P, Sun JX, Wang ZN. High platelet-to-lymphocyte ratio predicts poor prognosis and clinicopathological characteristics in patients with breast cancer: a meta-analysis. Biomed Res Int. 2017;2017:9503025. https://doi.org/10.1155/2017/9503025
20. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74. https://doi.org/10.1016/j.cell.2011.02.013
21. Takeuchi H, Abe M, Takumi Y, Hashimoto T, Kobayashi K, Osoegawa A, et al. The prognostic impact of the platelet distribution width-to-platelet count ratio in patients with breast cancer. PLoS One. 2017;12(12):e0189166. https://doi.org/10.1371/journal.pone.0189166
22. Ethier JL, Desautels D, Templeton A, Shah PS, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Res. 2017;19(1):2. https://doi.org/10.1186/s13058-016-0794-1
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Camila Macedo Boaro, Laura Mendonça Diefenthäeler, Gabriela Krüger da Costa, Katsuki Arima Tiscoski, Rafael José Vargas Alves, Maiquidieli Dal Berto, Claudia Giuliano Bica
This work is licensed under a Creative Commons Attribution 4.0 International License.
